Healthcare provider profile · identity verified

Ashraf Abdullah, MD

Allopathic & Osteopathic Physicians|Internal Medicine · LANSING, MI · NPI 1821006594

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ashraf Abdullah, MD received $134.98 in general payments during 2025 across 2 reported records.

Lilly USA, LLC accounted for 88.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$134.98

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$118.83	88.0%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$16.15	12.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$134.98	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FASENRA Normalized: fasenra	Biological	AstraZeneca Pharmaceuticals LP	$16.15	1	2025
Source payment records 2025-02-24 · AstraZeneca Pharmaceuticals LP · $16.15 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	51	15
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	226	68
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	75	18
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	58	16

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1013	294
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	844	126
Amlodipine Besylate	Amlodipine Besylate	811	246
Losartan Potassium	Losartan Potassium	729	219
Lisinopril	Lisinopril	614	175
Levothyroxine Sodium	Levothyroxine Sodium	514	139
Metformin Hcl	Metformin Hcl	468	152
Gabapentin	Gabapentin	427	106
Tamsulosin Hcl	Tamsulosin Hcl	411	137
Metoprolol Succinate	Metoprolol Succinate	410	131
Simvastatin	Simvastatin	409	122
Omeprazole	Omeprazole	374	117
Albuterol Sulfate Hfa	Albuterol Sulfate	355	141
Rosuvastatin Calcium	Rosuvastatin Calcium	332	112
Tramadol Hcl	Tramadol Hcl	307	66
Alprazolam	Alprazolam	303	55
Pantoprazole Sodium	Pantoprazole Sodium	301	111
Januvia	Sitagliptin Phosphate	251	67
Trazodone Hcl	Trazodone Hcl	244	64
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	242	57
Fluticasone Propionate	Fluticasone Propionate	230	83
Jardiance	Empagliflozin	226	68
Enalapril Maleate	Enalapril Maleate	214	60
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	206	43
Eliquis	Apixaban	204	55
Glipizide Er	Glipizide	192	63
Montelukast Sodium	Montelukast Sodium	191	55
Hydrochlorothiazide	Hydrochlorothiazide	189	56
Metoprolol Tartrate	Metoprolol Tartrate	186	58
Atenolol	Atenolol	181	56
Ezetimibe	Ezetimibe	180	56
Allopurinol	Allopurinol	175	55
Furosemide	Furosemide	175	62
Ibuprofen	Ibuprofen	168	67
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	155	61
Clonidine Hcl	Clonidine Hcl	149	42
Clopidogrel	Clopidogrel Bisulfate	147	45
Carvedilol	Carvedilol	144	46
Tizanidine Hcl	Tizanidine Hcl	144	47
Escitalopram Oxalate	Escitalopram Oxalate	142	43
Metformin Hcl Er	Metformin Hcl	142	48
Potassium Chloride	Potassium Chloride	142	47
Alendronate Sodium	Alendronate Sodium	141	49
Pravastatin Sodium	Pravastatin Sodium	132	39
Pioglitazone Hcl	Pioglitazone Hcl	131	40
Citalopram Hbr	Citalopram Hydrobromide	127	36
Meloxicam	Meloxicam	121	49
Ozempic	Semaglutide	113	31
Zolpidem Tartrate	Zolpidem Tartrate	112	30
Glimepiride	Glimepiride	111	34
Famotidine	Famotidine	106	35
Sertraline Hcl	Sertraline Hcl	105	36
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	93	28
Mirtazapine	Mirtazapine	92	32
Nifedipine Er	Nifedipine	91	24
Xarelto	Rivaroxaban	83	28
Chlorthalidone	Chlorthalidone	82	23
Duloxetine Hcl	Duloxetine Hcl	81	20
Ropinirole Hcl	Ropinirole Hcl	80	26
Fenofibrate	Fenofibrate Nanocrystallized	77	18
Mounjaro	Tirzepatide	75	18
Clonazepam	Clonazepam	73	18
Finasteride	Finasteride	72	22
Diclofenac Sodium	Diclofenac Sodium	71	45
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	71	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	70	24
Fluoxetine Hcl	Fluoxetine Hcl	70	20
Meclizine Hcl	Meclizine Hcl	66	31
Bupropion Xl	Bupropion Hcl	64	20
Levetiracetam	Levetiracetam	61	18
Bumetanide	Bumetanide	60	19
Spironolactone	Spironolactone	58	19
Trulicity	Dulaglutide	58	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	18
Quetiapine Fumarate	Quetiapine Fumarate	57	15
Buspirone Hcl	Buspirone Hcl	55	16
Ondansetron Hcl	Ondansetron Hcl	54	18
Donepezil Hcl	Donepezil Hcl	52	15
Lovastatin	Lovastatin	52	14
Farxiga	Dapagliflozin Propanediol	51	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	16
Nystatin	Nystatin	50	21
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	49	suppressed
Topiramate	Topiramate	49	13
Oxybutynin Chloride Er	Oxybutynin Chloride	48	15
Prednisone	Prednisone	47	37
Acyclovir	Acyclovir	46	16
Cephalexin	Cephalexin	45	41
Myrbetriq	Mirabegron	45	13
Celecoxib	Celecoxib	44	13
Glipizide	Glipizide	43	19
Hydralazine Hcl	Hydralazine Hcl	43	13
Lorazepam	Lorazepam	43	suppressed
Baclofen	Baclofen	41	suppressed
Memantine Hcl	Memantine Hcl	41	13
Pregabalin	Pregabalin	41	suppressed
Paroxetine Hcl	Paroxetine Hcl	40	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	39	suppressed
Fenofibrate	Fenofibrate	39	14
Amitriptyline Hcl	Amitriptyline Hcl	38	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	38	18
Ventolin Hfa	Albuterol Sulfate	38	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	11
Naproxen	Naproxen	37	21
Venlafaxine Hcl Er	Venlafaxine Hcl	37	11
Novolog Flexpen	Insulin Aspart	36	11
Azithromycin	Azithromycin	35	31
Bupropion Hcl Sr	Bupropion Hcl	34	11
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	13
Nitroglycerin	Nitroglycerin	33	18
Entresto	Sacubitril/Valsartan	32	11
Propranolol Hcl Er	Propranolol Hcl	32	suppressed
Sucralfate	Sucralfate	32	14
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	29	suppressed
Hydrocortisone	Hydrocortisone	29	18
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	28	14
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Lidocaine	Lidocaine	28	12
Valacyclovir	Valacyclovir Hcl	28	14
Diazepam	Diazepam	27	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Gemfibrozil	Gemfibrozil	25	suppressed
Ciclopirox	Ciclopirox Olamine	24	15
Risperidone	Risperidone	24	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Amiodarone Hcl	Amiodarone Hcl	23	suppressed
Repatha Sureclick	Evolocumab	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	14
Aripiprazole	Aripiprazole	22	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	22	11
Clotrimazole	Clotrimazole	21	16
Colchicine	Colchicine	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	15
Dulera	Mometasone/Formoterol	20	suppressed
Linzess	Linaclotide	20	suppressed
Metformin Er Osmotic	Metformin Hcl	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Temazepam	Temazepam	20	suppressed
Lamotrigine	Lamotrigine	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	18	suppressed
Estradiol	Estradiol	18	suppressed
Gemtesa	Vibegron	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Torsemide	Torsemide	17	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	14
Isosorbide Dinitrate	Isosorbide Dinitrate	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Phenobarbital	Phenobarbital	16	suppressed
Vraylar	Cariprazine Hcl	16	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	15	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Novolog	Insulin Aspart	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Asa-Butalb-Caffeine-Codeine	Codeine/Butalbital/Asa/Caffein	14	suppressed
Chlordiazepoxide-Clidinium	Chlordiazepoxide/Clidinium Br	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Tadalafil	Tadalafil	14	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Dimethyl Fumarate	Dimethyl Fumarate	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Fluconazole	Fluconazole	12	12
Humalog Kwikpen U-200	Insulin Lispro	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Mirabegron Er	Mirabegron	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Valsartan	Valsartan	12	suppressed
Colesevelam Hcl	Colesevelam Hcl	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Invokana	Canagliflozin	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Novofine 32	Pen Needle, Diabetic	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$134.98 · 2 records	Lilly USA, LLC	FASENRA	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error